- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Duality Biotherapeutics: First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 279 | PR Newswire | SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| 20.06. | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025 | - | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES | 1 | HKEx | ||
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.06. | Duality Biologics: Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting | 434 | PR Newswire | SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary... ► Artikel lesen | |
| 28.05. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 20, 2025 | - | HKEx | ||
| 28.05. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.05. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | 1 | HKEx | ||
| 23.05. | Duality Biotherapeutics: FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 102 | PR Newswire | Phase 1/2 first-in-human clinical study planned this year
SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606)... ► Artikel lesen | |
| 22.05. | Jefferies sets Duality Bio stock Buy rating, HK$500 PT | 3 | Investing.com | ||
| 12.05. | DUALITYBIO-B (09606): STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | 1 | HKEx | ||
| 09.05. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 06.05. | DUALITYBIO-B (09606): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION | - | HKEx | ||
| 06.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 06.05.2025 | 488 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.05.2025
Aktien
1 KYG2929M1087 Duality Biotherapeutics... ► Artikel lesen | |
| 29.04. | DUALITYBIO-B (09606): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | DUALITYBIO-B (09606): EXEMPTION UNDER RULE 13.46(2) OF THE LISTING RULES REGARDING 2024 ANNUAL REPORT | - | HKEx | ||
| 24.04. | Chinese Biopharma Firms Chase Hong Kong IPO, After DualityBio's Sizzling Debut | 1 | Benzinga.com | ||
| 15.04. | Irrer Börsengang: BioNTech-Partner DualityBio explodiert am ersten Handelstag | 3.228 | Der Aktionär | Die Börse in Hongkong ist seit dem heutigen Mittwoch um ein Biotech-Unternehmen reicher. Duality Biotherapeutics (DualityBio) hat einen furiosen Start auf das Parkett gezaubert - nicht zuletzt dank... ► Artikel lesen | |
| 15.04. | BRIEF: Duality Biotherapeutics surges in Hong Kong trading debut | 2 | Bamboo Works | ||
| 15.04. | China's Duality Biotherapeutics surges over 200% in Hong Kong trading debut | 5 | Investing.com | ||
| 14.04. | DUALITYBIO-B (09606): ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS | 1 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,085 | -0,46 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen auf "Buy" belassen. Die Ergebnisse dürften im Rahmen der Ziele des Diagnostik-Unternehmens liegen, schrieb Jan Koch... ► Artikel lesen | |
| EVOTEC | 7,302 | +2,79 % | DEUTSCHE BANK RESEARCH stuft Evotec auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Evotec mit einem Kursziel von 7 Euro auf "Hold" belassen. Analyst Fynn Scherzler wagte am Mittwoch einen Ausblick auf den... ► Artikel lesen | |
| BIONTECH | 94,00 | -0,90 % | BioNTech-Konkurrent Moderna: Aktie mit Kurssprung - was ist da los? | Die Aktie von Moderna hat am Dienstag einen kräftigen Kurssprung hinlegen können. Das Papier ging als Top-Gewinner des Tages im S&P 500 vor Intel und Albemarle aus dem Handel. Moderna notiert nun so... ► Artikel lesen | |
| LONGEVITY HEALTH | 5,800 | +114,81 % | Pre-market Movers: Longevity Health, SMX (Security Matters), Brazil Potash, Cyclacel Pharmaceuticals, Presidio Property Trust | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.15 A.M. ET).In the Green Longevity Health Holdings, Inc. (XAGE) is up over... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,220 | -1,14 % | Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia | Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition... ► Artikel lesen | |
| PROKIDNEY | 3,395 | -8,74 % | ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel | FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT... ► Artikel lesen | |
| NUVALENT | 82,99 | -2,05 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,720 | -5,62 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| COGENT BIOSCIENCES | 11,500 | +3,60 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
| CARGO THERAPEUTICS | 4,605 | +0,44 % | Cargo Therapeutics, Inc.: CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right | SAN CARLOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. ("CARGO" or the "Company") (NASDAQ: CRGX), a biotechnology company that has focused on developing CAR T-cell therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,580 | -7,42 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,980 | -3,70 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,370 | -4,13 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| CUREVAC | 4,662 | -0,30 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| KAIROS PHARMA | 1,180 | +70,77 % | Kairos Pharma Stock Soars After Positive Interim Results From Phase 2 Trial Of ENV-105 |
Das Unternehmen DUALITY BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 32,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.